– UK, Cambridge – Feedback plc (AIM:FDBK), the specialist medical imaging technology company, announces the appointment of Simon Sturge as Non-Executive Director with immediate effect.
Mr Sturge joined Merck Healthcare in 2014 and is currently Chief Operating Officer and member of the Healthcare Executive Committee. He is an experienced healthcare executive in the UK and has built a very strong reputation not only in the biotechnology industry but also in the investment community. His experience includes eight years at Celltech, and he was the founder and CEO of RiboTargets which later reversed into Vernalis Plc. After serving as CEO of OctoPlus N.V. for two years, he became Senior Vice President of Boehringer Ingelheim’s Biopharmaceutical Business. Mr Sturge is a regular speaker at conferences including the World Economic Forum.
Dr Alastair Riddell, Chairman of Feedback, said: “Since joining Feedback I have been impressed by the potential of its products in improving patient management. As the Company transforms into a unified structure with a focus on commercial development, it will benefit greatly from the vision, experience and breadth of reach of Simon in the healthcare field to help realise its full potential.”
Simon Sturge, Non-Executive Director of Feedback, commented: “I am very excited to have the opportunity to join the Board of Feedback. We see that in many fields of healthcare there is substantial value in being a depositary of a large volume of data and even more value in being able to intelligently interpret such data. I truly feel that textural mapping of tumours will have a significant impact on the way we undertake the development of new pharmaceutical products to increase focus toward personalised treatments as well as improving the diagnosis and treatment of cancer. I believe that Feedback has an advantage in being an early mover in this field and look forward to taking on an active role as a non-executive director in shaping this next stage in the Company’s development.”
About Feedback plc
Feedback plc is a specialist medical imaging technology company. It develops software and systems that provide innovative techniques and improved workflows for practitioners involved in medical research and treating patients. TexRAD, the Company’s patented quantitative image texture analysis technology, has the potential to assist clinicians in diagnosis, prognosis and treatment of patients with cancer and is currently installed in over 40 of the world’s leading research institutions across Europe, North America, Asia and Australasia. The Cadran platform provides a suite of medical imaging tools for decision support. The Cadran range includes the picture archiving communication system to provide decision support for scan analysis, diagnostic workstations which provide secure remote access to view scans on demand, and products to securely share and transport patient data.
For more information : www.fbk.com
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.